🚀 OBI Pharma has enrolled the first patient in our Phase 1/2 clinical trial of OBI-902, our first TROP2-targeted ADC built with our proprietary GlycOBI® technology.
🔗 Learn more: www.globenewswire.com/news-release...
#OBIPharma #ADC #ClinicalTrials
#GlycOBI #OBI902 #Phase1 #firstpatientin
0
0
0
0